因塞特医疗(INCY)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

INCY 因塞特医疗

交易中 05-09 14:39:07 EDT

53.39

-0.12

-0.22%

最高53.93	最低53.10	成交量68.52万
今开53.76	昨收53.51	日振幅1.55%
总市值119.88亿	流通市值99.69亿	总股本2.25亿
成交额3,655万	换手率0.37%	流通股本1.87亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"INCY","market":"US","secType":"STK","nameCN":"因塞特医疗","latestPrice":53.39,"timestamp":1715279943869,"preClose":53.51,"halted":0,"volume":685160,"delay":0,"floatShares":186717759,"shares":224540751,"eps":3.298486,"marketStatus":"交易中","marketStatusCode":2,"change":-0.12,"latestTime":"05-09 14:39:07 EDT","open":53.76,"high":53.93,"low":53.1,"amount":36547649.873840004,"amplitude":0.015511,"askPrice":53.4,"askSize":823,"bidPrice":53.38,"bidSize":40,"shortable":3,"etf":0,"ttmEps":3.298486,"exchange":"NASDAQ","tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1715284800000},"adr":0,"adjPreClose":53.51,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":53.91,"preClose":53.51,"latestTime":"09:26 EDT","volume":11533,"amount":617921.41715,"timestamp":1715261200775},"postHourTrading":{"tag":"盘后","latestPrice":53.51,"preClose":53.51,"latestTime":"19:48 EDT","volume":231633,"amount":12399727.1896,"timestamp":1715212121227},"volumeRatio":0.451089},"requestUrl":"/m/hq/s/INCY/wiki","defaultTab":"wiki","newsList":[{"id":"2433403581","title":"因塞特2024财年第一财季实现净利润1.70亿美元，同比增加683.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2433403581","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2433403581?lang=zh_cn&edition=full","pubTime":"2024-05-05 00:22","pubTimestamp":1714839769,"startTime":"0","endTime":"0","summary":"3月31日，因塞特公布财报，公告显示公司2024财年第一财季净利润为1.70亿美元，同比增加683.41%；其中营业收入为8.81亿美元，同比增加8.90%，每股基本收益为0.76美元。从资产负债表来看，因塞特总负债17.41亿美元，其中短期债务8.46百万美元，资产负债比为4.10，流动比率为3.48。机构评级：截至2024年3月31日，当前有19家机构对因塞特目标价做出预测，其中目标均价为72.01美元，其中最低目标价为52.00美元，最高目标价为86.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050500230087d1fd9b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050500230087d1fd9b&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2432571925","title":"Truist Securities：重申Incyte(INCY.US)评级，由买入调整至买入评级, 目标价由84.00美元调整至83.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2432571925","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2432571925?lang=zh_cn&edition=full","pubTime":"2024-05-01 20:55","pubTimestamp":1714568152,"startTime":"0","endTime":"0","summary":"Truist Securities：重申Incyte(INCY.US)评级，由买入调整至买入评级, 目标价由84.00美元调整至83.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405012055538b69e946&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405012055538b69e946&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431245383","title":"因主导药物销售疲软，Incyte 公司季度利润不及预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2431245383","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2431245383?lang=zh_cn&edition=full","pubTime":"2024-04-30 22:10","pubTimestamp":1714486213,"startTime":"0","endTime":"0","summary":"    路透4月30日 - Incyte公司  周二公布的第一季度利润低于华尔街预期，原因是其血癌药物Jakafi销售疲软，导致其股价下跌2.4%。4 月份，该公司还宣布达成了收购 Escient Pharmaceuticals 公司的最终协议。报告季度的总收入为 8.809 亿美元，低于预期的 9.236 亿美元。该制药公司第一季度的特许权使用费收入为1.26亿美元，同比增长9%。除去其他项目，这家美国制药商本季度每股收益为 64 美分，低于预期的每股 84 美分。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2431347724","title":"BUZZ-营收和利润低于预期，Incyte Corp 下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2431347724","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2431347724?lang=zh_cn&edition=full","pubTime":"2024-04-30 20:54","pubTimestamp":1714481644,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    4月30日 - ** 制药商Incyte公司  股价盘前下跌2.9%至51美元 ** 该公司第一季度营收为8.809亿美元，同比增长9%，但低于分析师预计的9.236亿美元--伦敦证券交易所集团数据 ** 第一季度每股副利润为64美分，也低于预期的每股84美分--伦敦证券交易所集团数据 ** 骨髓癌药物Jakafi的收入为5.718亿美元，去年同期为5.8亿美元。 ** 公司称 \"本季度的收入增长被Jakafi的库存缩减所抵消\"。** 截至上一交易日收盘，股价累计下跌 16.3","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2430769822","title":"Incyte Corp    预计每股收益 84 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2430769822","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2430769822?lang=zh_cn&edition=full","pubTime":"2024-04-26 20:07","pubTimestamp":1714133244,"startTime":"0","endTime":"0","summary":"   * Incyte公司   在4月30日公布的截至2024年3月31日的财报中预计季度收入将有所增长。* 根据LSEG的数据，17位分析师的平均预期显示，这家总部位于美国特拉华州威尔明顿的公司的营收将从去年同期的8.0867亿美元增长14.6%，达到9.26533亿美元。   * LSEG 分析师对 Incyte Corp 的平均预期为每股收益 84 美分。* 华尔街对 Incyte Corp 的 12 个月目标价中值为 77.00 美元，高于其上一交易日 51.18 美元的收盘价。4月26日 - 以前季度业绩。除非另有说明，否则所有数据均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2412667067","title":"因塞特2023财年实现净利润5.98亿美元，同比增加75.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2412667067","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2412667067?lang=zh_cn&edition=full","pubTime":"2024-02-17 00:21","pubTimestamp":1708100487,"startTime":"0","endTime":"0","summary":"12月31日，因塞特公布财报，公告显示公司2023财年净利润为5.98亿美元，同比增加75.37%；其中营业收入为36.96亿美元，同比增加8.87%，每股基本收益为2.67美元。从资产负债表来看，因塞特总负债16.32亿美元，其中短期债务9.13百万美元，资产负债比为4.19，流动比率为3.75。机构评级：截至2023年12月31日，当前有19家机构对因塞特目标价做出预测，其中目标均价为75.79美元，其中最低目标价为58.00美元，最高目标价为93.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240217002136879793df&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240217002136879793df&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2411322694","title":"美国研究综述-布鲁克公司、Cymabay Therapeutics、SSR 矿业公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2411322694","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2411322694?lang=zh_cn&edition=full","pubTime":"2024-02-14 15:35","pubTimestamp":1707896137,"startTime":"0","endTime":"0","summary":"    路透社2月14日 - 华尔街证券分析师周三调整了对布鲁克公司、Cymabay Therapeutics 和 SSR 矿业公司等几家美国上市公司的评级和目标价。要点             * 布鲁克公司  ：摩根大通将其评级从中性上调至增持             * Cymabay Therapeutics Inc   ：Piper Sandler将其评级从 \"增持 \"下调至 \"中性\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2410032871","title":"Incyte Corp   预计每股收益1.16美元 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2410032871","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2410032871?lang=zh_cn&edition=full","pubTime":"2024-02-09 20:02","pubTimestamp":1707480146,"startTime":"0","endTime":"0","summary":"   * Incyte公司   将于2月13日公布截至2023年12月31日的业绩报告，预计该公司的季度收入将有所增长。* 根据LSEG的数据，17位分析师的平均预期显示，这家总部位于美国特拉华州威尔明顿的公司的营收预计将从去年同期的9.267亿美元增至10.02亿美元，增幅为8.1%。   * LSEG 分析师对 Incyte Corp 的平均预期为每股收益 1.16 美元。* 华尔街对 Incyte Corp 的 12 个月目标价中位数为 77.00 美元，高于其上次收盘价 57.36 美元。2月9日 - 以前季度业绩。除非另有说明，所有数字均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2409458057","title":"BUZZ-路透报道诺华正在进行收购谈判后，MorphoSys 大涨 50","url":"https://stock-news.laohu8.com/highlight/detail?id=2409458057","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2409458057?lang=zh_cn&edition=full","pubTime":"2024-02-06 01:53","pubTimestamp":1707155631,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    2月5日 - ** 据报道，制药商诺华（Novartis）  正在就收购这家药物开发商进行深入谈判。** MOR股价最高升至16.97美元，创下2021年7月以来的最高水平** 路透（(link)）援引两名知情人士的话报道说，诺华战胜了竞争对手Incyte公司  ，开始与MorphoSys公司进行收购谈判。** MorphoSys开发抗致命癌症药物** 随着本交易日的走势，在美国上市的公司股价在过去一年中上涨了约 230","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2402429928","title":"BUZZ-皮炎药物试验受挫，BTIG 将 Aclaris 的评级下调至 \"中性\"。","url":"https://stock-news.laohu8.com/highlight/detail?id=2402429928","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2402429928?lang=zh_cn&edition=full","pubTime":"2024-01-11 20:29","pubTimestamp":1704976144,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    1月11日 - ** 药物开发商Aclaris Therapeutics   股价盘前下跌3.8%至97美分** 券商BTIG将该公司股票评级从 \"买入 \"下调至 \"中性\"** 该公司周三报告说 (link)，在一项中期试验的第二部分中，其特异性皮炎日服一次型药物没有显示出统计学意义** 特应性皮炎会引起瘙痒，导致皮肤发红、肿胀和皲裂** 每日两","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2391711379","title":"因塞特盘中异动 快速拉升5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2391711379","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2391711379?lang=zh_cn&edition=full","pubTime":"2023-12-12 23:48","pubTimestamp":1702396117,"startTime":"0","endTime":"0","summary":"北京时间2023年12月12日23时48分，因塞特股票出现异动，股价急速拉升5.10%。截至发稿，该股报59.95美元/股，成交量100.7万股，换手率0.45%，振幅4.83%。机构评级方面，在所有22家参与评级的机构中，50%的券商给予买入建议，50%的券商给予持有建议，无券商给予卖出建议。因塞特股票所在的生物技术行业中，整体涨幅为0.21%。该公司的第一个皮肤科产品 Opzelura 于 2021 年被批准用于特应性皮炎，2022 年被批准用于白斑病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20231212234838830c4191&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20231212234838830c4191&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.incyte.com","stockEarnings":[{"period":"1week","weight":0.0108},{"period":"1month","weight":-0.028},{"period":"3month","weight":-0.0671},{"period":"6month","weight":0.0204},{"period":"1year","weight":-0.1738},{"period":"ytd","weight":-0.1478}],"compareEarnings":[{"period":"1week","weight":0.0337},{"period":"1month","weight":-0.0029},{"period":"3month","weight":0.0379},{"period":"6month","weight":0.1738},{"period":"1year","weight":0.2586},{"period":"ytd","weight":0.0881}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"因塞特医疗公司于1991年在特拉华州注册成立。公司是一家生物制药公司，专注于专利小分子药物的发现、开发和商业化，以治疗严重未满足的医疗需求。","yearOnYearQuotes":[{"month":1,"riseRate":0.612903,"avgChangeRate":0.086816},{"month":2,"riseRate":0.322581,"avgChangeRate":-0.001636},{"month":3,"riseRate":0.451613,"avgChangeRate":-0.034195},{"month":4,"riseRate":0.451613,"avgChangeRate":-0.012683},{"month":5,"riseRate":0.612903,"avgChangeRate":0.059961},{"month":6,"riseRate":0.566667,"avgChangeRate":0.022585},{"month":7,"riseRate":0.5,"avgChangeRate":0.011147},{"month":8,"riseRate":0.5,"avgChangeRate":0.015891},{"month":9,"riseRate":0.366667,"avgChangeRate":-0.021122},{"month":10,"riseRate":0.5,"avgChangeRate":0.021159},{"month":11,"riseRate":0.566667,"avgChangeRate":0.061353},{"month":12,"riseRate":0.633333,"avgChangeRate":0.104243}],"exchange":"NASDAQ","name":"因塞特医疗","nameEN":"Incyte"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"因塞特医疗(INCY)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供因塞特医疗(INCY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"因塞特医疗,INCY,因塞特医疗股票,因塞特医疗股票老虎,因塞特医疗股票老虎国际,因塞特医疗行情,因塞特医疗股票行情,因塞特医疗股价,因塞特医疗股市,因塞特医疗股票价格,因塞特医疗股票交易,因塞特医疗股票购买,因塞特医疗股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"因塞特医疗(INCY)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供因塞特医疗(INCY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}